Результаты поиска

Fractal Dimension Analysis of Mandibular Trabecular Bone in Patients Receiving Antiresorptive Therapy for Osteoporosis and Oncologic Conditions.

Objectives: This study aimed to assess the effects of antiresorptive drugs on mandibular trabecular bone structure in patients with osteoporosis and those receiving antiresorptive therapy for oncologic conditions using fractal dimension (FD) analysis of panoramic radiographs. Additionally, it investigated the influences of age, gender, drug type, administration route, and treatment duration on mandibular trabecular bone structure. Methods: This retrospective cross-sectional study included 73 patients categorized into the following three groups: 23 osteoporosis patients, 25 oncologic patients,

Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis.

BACKGROUND: Teriparatide (TPTD) is a widely used anabolic agent for the treatment of osteoporosis. Several factors have been identified to be related to bone mineral density (BMD) increase in anti-osteoporosis treatment with other agents; however, there has been no systematic analysis to summarize the associated determinants of BMD reaction to daily teriparatide treatment. METHODS: In this retrospective study, we performed a comprehensive investigation involving not only clinical data but also several relevant lifestyle factors to be examined for their potential contribution to BMD response.

Совпадение в полном тексте источника
… Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Mineral Res. 2013;28(6):1328–1336. doi: 10.1002/jbmr.1853. 31. … Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rhuematol. 2010;37(1):141–148. doi: 10.3899/jrheum.090411. 50. …

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.

Skeletal-related events (SREs) including pain, fractures, and hypercalcemia are a major source of morbidity for cancer patients with bone metastases. The receptor activator of NF-κB ligand (RANKL) is a key mediator of osteoclast formation and activity in normal bone physiology as well as cancer-induced bone resorption. The first commercially available drug that specifically targets and inhibits the RANKL pathway is denosumab, a fully human monoclonal antibody that binds and neutralizes RANKL, thereby inhibiting osteoclast function. In this review, we summarize the major studies leading to the

Совпадение в полном тексте источника
… measurements corresponding to a T score of −2.0 to −4.0 who had been receiving alendronate at 70 mg/week for at least 6 months were eligible. … Subjects were randomized to denosumab 60 mg subcutaneously every 6 months versus continuing oral alendronate. All subjects were supplied with calcium and vitamin D supplements daily. …

The efficiency of risedronate in reducing bone resorption after total hip arthroplasty: a meta-analysis of randomized control trials at a minimum of 6 months' follow-up.

BackgroundRecently risedronate is suggested to be effective for the prevention and treatment of for osteoporosis in total hip arthroplasty. This meta-analysis aimes to evaluate the efficacy of risedronate in reducing femoral periprosthetic bone mineral density loss in patients undergoing primary total hip arthroplasty.MethodsA systematic search was performed in Medline (1966-31 October 2017), PubMed (1966-31 October 2017), Embase (1980-31 October 2017), ScienceDirect (1985-31 October 2017) and the Cochrane Library. Only randomized controlled trial (RCT) were included. Fixed/random effect model

Совпадение в полном тексте источника
… Previous studies have reported an occasional occurrence of a subtrochanteric femoral fracture in patients with osteoporosis after long-term use of alendronate which raised concerns for the bisphosphonate application [ 30 ]. … Capeci CM Tejwani NC Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy J Bone Joint Surg Am 2009 91 11 2556 2561 10.2106/JBJS.H.01774 19884427 …

Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives.

With the progressive aging of the population, osteoporosis has gradually grown into a global health problem for men and women aged 50 years and older because of its consequences in terms of disabilities and fragility fractures. This is especially true in the People's Republic of China, which has the largest population and an increasing proportion of elderly people, as osteoporosis has become a serious challenge to the Chinese government, society, and family. Apart from the fact that all osteoporotic fractures can increase the patient's morbidity, they can also result in fractures of the hip an

Совпадение в полном тексте источника
… Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12(1):1–12. 158. Bone HG, Hosking D, Devogelaer JP, et al. … Alendronate Phase III Osteoporosis Treatment Study Group Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–1199. doi: 10.1056/NEJMoa030897. 159. Harrington JT, Ste-Marie LG, Brandi ML, et al. …

Как готовить пациентов, получающих антирезортивную терапию, к извлечению зубов: обзор.

Бифосфонаты (БП) и Деносумаб (ДМБ) являются антирепрессивными агентами (АА), обычно используемыми для лечения остеопороза, множественной миеломы (8,0%), рака груди (3,3%), рака простаты (2,9 процента) и других магнелез (0,7 процента), метастаза кости и гиперкальцемии, вызванной раком. Однако эта терапия связана со значительным риском связанного с лекарствами остеонекроза челюсти (MRONJ), особенно после выведения зубов. Цель этого описательного обзора заключалась в обобщении текущих данных о мерах, направленных на снижение риска ДРОНЖ после извлечения зубов, и в критическом обсуждении достоверн

Совпадение в полном тексте источника
… Most of them were treated with alendronate, while one patient received denosumab. However, the specific type of PRF used in this study was not specified. … Post-fracture mortality is higher in people who discontinue Risedronate than Alendronate administered orally [ 67 ]. …

Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system.

ObjectiveThis project aims to identify the top 30 drugs most commonly associated with constipation and their signal values within the FDA Adverse Event Reporting System database.MethodsWe extracted adverse drug events (ADEs) related to constipation from the FAERS database spanning from January 1, 2004, to September 30, 2023. We compiled the 30 most frequently reported drugs based on the frequency of constipation events. We employed signal detection methodologies to ascertain whether these drugs elicited significant signals, including reporting odds ratio, proportional reporting ratio, multi-it

Совпадение в полном тексте источника
… Sex hormones and insulins (teriparatide), genito urinary system and sex hormones (solifenacin succinate), and musculo-skeletal system (alendronate sodium) were also reported. TABLE 2 Top 30 constipation-related medications by frequency in the FAERS database, January 1, 2004 to September 30, 2023. … We found that lenalidomide, adalimumab, niraparib, erenumab, sevelamer carbonate, teriparatide, palbociclib, patiromer, varenicline, orlistat, pomalidomide, oxycodone, dimethyl fumarate, enzalutamide, exenatide, cabozantinib, clozapine, semaglutide, nintedanib, solifenacin succinate, alendronate sodium …

A bibliometric research based on hotspots and frontier trends of denosumab.

Denosumab is a monoclonal antibody that targets and inhibits the osteoclast activating factor receptor activator for nuclear factor-κB ligand (RANKL). It has been widely used in the treatment of osteoporosis, giant cell tumors of bone, and in the prevention of malignant skeletal-related events (SREs). We collected the research results and related MeSH terms of denosumab from 2011 to 2021 through the Web of Science and PubMed, respectively. The literature was visualized and analyzed by CiteSpace and bibliometric online analysis platforms. The MeSH terms were biclustered using the Bibliographic

Совпадение в полном тексте источника
… The postmenopausal women were most concerned with the OP themes, and much of the research focused on comparing denosumab with ZA, alendronate, and teriparatide by monitoring BMD and BTM. … Differing effects of denosumab and alendronate on cortical and trabecular bone . Bone 59 , 173 – 179 . 10.1016/j.bone.2013.11.016 24275677 Zhang N. Zhang Z. K. Yu Y. Zhuo Z. Zhang G. Zhang B. T. ( 2020 ). …

Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.

Bone metastasis is the leading cause of death in prostate cancer patients, for which there is currently no effective treatment. Since the bone microenvironment plays an important role in this process, attentions have been directed to the interactions between cancer cells and the bone microenvironment, including osteoclasts, osteoblasts, and bone stromal cells. Here, we explained the mechanism of interactions between prostate cancer cells and metastasis-associated cells within the bone microenvironment and further discussed the recent advances in targeted therapy of prostate cancer bone metasta

Совпадение в полном тексте источника
… Currently, alendronate (Fosamax) [ 95 ], zoledronate (Zometa) [ 96 ], and clodronate (Bonefos) [ 97 ] are used in the clinic. … In this study, the nanoparticles were also modified with alendronate for targeting bone [ 107 ]. Indeed, in vitro and in vivo studies have shown that this drug delivery system has a good bone-targeting ability and treatment effect [ 108 ]. …

Nanoparticle Strategies for Bone Metastasis Immunotherapy: Targeting, Immune Reprogramming and Combination Therapy.

Bone metastases remain one of the most clinically devastating complications of advanced cancer, particularly in breast, prostate, and lung malignancies, where they drive pain, fractures, hypercalcemia, and progressive functional decline. Their management is further complicated by a highly immunosuppressive bone microenvironment characterized by osteoclast-driven bone destruction, myeloid cell dominance, impaired antigen presentation, and weak effector T-cell infiltration, all of which limit the activity of conventional immunotherapies. In this setting, nanoparticles are emerging not merely as

Совпадение в полном тексте источника
… Likewise, branched polyethylenimine (PEI)–alendronate conjugates (PCA/miR-34a) have exhibited improved bone accumulation and inhibition of osteolysis [ 180 ]. … Liu et al. developed a multifunctional nanoplatform consisting of a ZIF-8 core loaded with SHH siRNA, a lipid shell containing docetaxel, and alendronate-functionalized surface ligands for bone targeting [ 219 ]. …

Managing bisphosphonate-related osteonecrosis of the jaws with xenografts: a case report.

It is possible to manage large bone destruction induced by BRONJ using xenograft grafting to promote a bone formation.

Совпадение в полном тексте источника
… In addition, she reported to have been diagnosed with osteoporosis, for which she had been taking oral alendronate 70 mg once weekly for over 10 years. A strong clinical suspicion of BRONJ was raised. … Esophagitis associated with the use of alendronate. N. Engl. J. Med. 335:1016–1021. 3. de Camargo Moraes, P. , Silva C. A., Soares A. B., Passador‐Santos F., Corrêa M. E., de Araújo N. S., et al. 2015. Tooth alterations in areas of bisphosphonate‐induced osteonecrosis. Clin. …

Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective.

In 2025, it will be 30 years since the initial clinical approval of pegylated liposomal doxorubicin (PLD) by the Food and Drug Administration. PLD predated the field of nanomedicine and became a model nanomedicine setting key pharmacological principles (prolonged circulation, slow drug release and the enhanced permeability and retention (EPR) effect) for clinical application of other nano-drugs in cancer therapy. The impressive reduction of cardiotoxicity conferred by PLD is the most valuable clinical asset. While PLD has gained a strong foothold in relapsed ovarian cancer and metastatic breas

Совпадение в полном тексте источника
… , an amino-bisphosphonate, and developed a formulation that co-encapsulates alendronate and doxorubicin. … This results in the formation of a complex salt that precipitates as rods within spherical vesicles. 137 Owing to the immune modulatory effects of alendronate, pegylated liposomal alendronate of doxorubicin, abbreviated as PLAD, demonstrates unique properties and superior activity when compared with …

Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte- and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study.

BACKGROUND: The aim of this study was to compare retrospectively the effect of three different treatment protocols on the healing outcome in patients with established medication-related osteonecrosis of the jaw (MRONJ). METHODS: A total of 34 MRONJ patients were recruited from the Department database and were divided according to the treatment protocols in a study group (G1) and two control groups (G2 and G3). G1 was treated with antibiotic therapy, surgery, leukocyte- and platelet-rich fibrin (L-PRF), and photobiomodulation; G2 was treated with antibiotic therapy and surgery; G3 was treated

Совпадение в полном тексте источника
… Ten patients (29.4%) received denosumab, 5 (14.7%) denosumab and zoledronate, 3 (8.8%) alendronate, 14 (41.2%) zoledronate, one patient (2.9%) received alendronate and zoledronate, and one patient (2.9%) received ibandronate. … Regarding the PBM effect in soft tissue healing, a study conducted by Lee et al. on a culture of alendronate-treated oral keratinocytes demonstrated that PBM inhibited apoptosis caused by alendronate. …

Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation.

OBJECTIVES: Medication-related osteonecrosis of the jaw (MRONJ) is a well-known side effect of certain drugs that are used to influence bone metabolism to treat osteometabolic disease or cancers. The purpose of our study was to investigate how high-concentration and low-concentration bisphosphonate (BP) intake affects the disease severity. MATERIALS AND METHODS: Data collected from the medical records of 52 patients treated with BPs, antiresorptive, antiangiogenic drugs and diagnosed with MRONJ were included in this study. Age, sex, type of systemic disease, type of drug, duration of drug tre

Совпадение в полном тексте источника
… Stage II MRONJ in a female patient treated with alendronate for os - teoporosis. D. Extra-oral draining fistula at the submandibular region of the jaw in a patient with stage 3 MRONJ. … Of the patients in Group II, 5 were using ibandronate (17.2%), 21 alendronate (72.4%), and 3 residronate (10.3%). …

Osteoporosis in Men: A Review of an Underestimated Bone Condition.

Osteoporosis is called the 'silent disease' because, although it does not give significant symptoms when it is not complicated, can cause fragility fractures, with serious consequences and death. Furthermore, the consequences of osteoporosis have been calculated to weigh heavily on the costs of health systems in all the countries. Osteoporosis is considered a female disease. Actually, the hormonal changes that occur after menopause certainly determine a significant increase in osteoporosis and the risk of fractures in women. However, while there is no doubt that women are more exposed to osteo

Совпадение в полном тексте источника
… Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol. Int. 2004;24:110–113. doi: 10.1007/s00296-003-0388-y. 111. … Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 2000;343:604–610. doi: 10.1056/NEJM200008313430902. 114. Boonen S., Orwoll E.S., Wenderoth D., Stoner K.J., Eusebio R., Delmas P.D. …

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review.

INTRODUCTION: Medication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone. To date, oral health preventive measures remain the most effective strategy to reduce MRONJ incidence, and, in this sense, the major goal is to diagnose, treat, and eradicate any oral diseases that could compromise oral health. The present systematic review aims to investigate the awareness of MRONJ among patients assuming BMAs. METHODS: A systematic literature sea

Совпадение в полном тексте источника
… . | 2010 | USA | 73 | 2/71 | 66 (44–88) | Osteoporosis: 54 (74%); Osteopenia: 16 (22%); Breast cancer: 1 (1%); Unknown: 2 (3%) | BPs | alendronate: 44 (60%); risedronate: 21 (29%); ibandronate: 7 (10%); zoledronate: 1 (1%) | 13 (18%) | n.d. … Based on the available data, 124 patients undergoing alendronate therapy, 38 patients risedronate therapy, 31 patients zoledronate therapy, 18 patients ibandronate therapy, 1 patient pamidronate therapy and 1 clodronate therapy. …

Efficacy of a nonsurgical treatment regimen in patients with bisphosphonate-related osteonecrosis of the jaws in Saudi Arabia.

ObjectivesThe objective of this study was to evaluate the effectiveness of a nonsurgical treatment regimen in the long-term control of necrotic areas of the jaws and pain in such patients.MethodsA total of 96 patients suffering from the disease were included in this study. All patients received nonsurgical treatment regimen for 10 days, and repeated every 3 months for 2 years. The size of the osteonecrotic lesions was measured and the pain level was self-assessed with a visual analog scale.ResultsThe patients showed a statistically significant (F = 16.1; p ConclusionsThis conservative nonsurgi

Совпадение в полном тексте источника
… Patients and methods A total of 96 patients (42 males and 54 females) with BRONJ and under treatment with different types of bisphosphonates (zoledronate, 45 patients; pamidronate, 27 patients; and alendronate, 24 patients) were allocated consecutively from those attending the oral and maxillofacial … N | Zoledronate | Pamidronate | Alendronate 96 | 45 | 27 | 24 Table 2. Duration of treatment with bisphosphonates at the beginning of regimen therapy (month). n | 10–19 months | 20–29 months | 30–40 months | 100–180 months 96 | 40 | 30 | 15 | 11 Table 3. …

Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database.

Medication-related osteonecrosis of the jaw (MRONJ) is associated with many drugs, including bisphosphonates (BPs). BPs are associated with atypical femoral fractures and osteonecrosis of the external auditory canal. Thus, many drugs are reported to cause adverse effects on bone. This study aimed to investigate the effects of drugs and patient backgrounds regarding osteonecrosis-related side effects, including MRONJ. This study used a large voluntary reporting database, namely, the Japanese Adverse Drug Event Report database. First, we searched for risk factors related to MRONJ using volcano p

Совпадение в полном тексте источника
… The most frequently reported were zoledronate in 1352 records (29.4%), alendronate in 780 records (17.0%), risedronate in 353 records (7.7%), and pamidronate in 252 records (5.5%). Denosumab was associated with 674 records (14.7%). … In this study, zoledronic acid used for malignant tumors was most frequently reported, and alendronate, risedronate, and minodronate used for osteoporosis were frequently reported ( Table 2 ). …

Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients.

Osteonecrosis (ON) is a complex and multifactorial complication of systemic lupus erythematosus (SLE). ON is a devastating condition that causes severe pain and compromises the quality of life. The prevalence of ON in SLE patients is variable, ranging from 1.7% to 52%. However, the pathophysiology and risk factors for ON in patients with SLE have not yet been fully determined. Several mechanisms for SLE patients' propensity to develop ON have been proposed. Glucocorticoid is a widely used therapeutic option for SLE patients and high-dose glucocorticoid therapy in SLE patients is strongly assoc

Совпадение в полном тексте источника
… A study by Agarwala et al of 60 ON patients, 10 of whom had SLE, showed that alendronate reduces pain, improves function, and delays ON progression. 151 One study analyzed the time from a diagnosis of ON to hip replacement as a marker for the ability of alendronate to minimize disease progression. … In the alendronate group, only six patients progressed to THA and the proportion of hips that developed collapse was also significantly smaller. …

Oral health status and quality of life in female patients receiving low dose bone-modifying agents for cancer treatment-induced bone loss: a single-center exploratory study.

INTRODUCTION: Breast cancer patients, undergoing low-dose bone-modifying agent (LD-BMA) therapy for cancer treatment-induced bone loss (CTIBL), represent an emerging category at risk of Medication-Related (MRONJ) low (<1%) but not absent. However, data on their oral health status and quality of life related are currently limited. This single-center exploratory study aimed to assess oral health conditions, periodontal status, and oral health-related quality of life in non-metastatic breast cancer patients under LD-BMA therapy for CTIBL. MATERIALS AND METHODS: Forty patients were consecutively

Совпадение в полном тексте источника
… Regarding BMA therapy, 17 patients received alendronate, 5 clodronate, 4 risedronate, and 14 denosumab (biannual dose of 60 mg). Based on LD-BMA therapy duration, the included patients were analysed and divided into two groups (group A <3 years vs. group B ≥ 3 years). … Table 1 Study population features. a Dosing regimens were as follows: Alendronate 70 mg orally once weekly; Clodronate 100 mg intramuscularly once weekly or 200 mg every two weeks; Risedronate 35 mg orally once weekly; Denosumab 60 mg subcutaneously every six months. …